Clinical validation of the dried blood spot analysis for antituberculosis drugs
Completed
- Conditions
- Blood concentration of anti TB drugs10028440
- Registration Number
- NL-OMON34891
- Lead Sponsor
- niversitair Medisch Centrum Groningen
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 33
Inclusion Criteria
- Adult (>18 years old)
- TB-patient who using at least one of the following drugs: Isoniazid, Pyrazinamide, Rifampicin, Ethambutol, clarithromycin, Amikacin, Kanamycin, Moxifloxacin, Linezolid
- TB-patient who is scheduled for routine TDM by the doctor.
- written informed consent
Exclusion Criteria
Patients with serious bleeding disorder
Study & Design
- Study Type
- Observational invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method <p>The correlation of laboratory analysis results from DBS method to conventional<br /><br>method</p><br>
- Secondary Outcome Measures
Name Time Method <p>The influence of origin of the bloodsample (finger prick or venous blood) on<br /><br>the concentration of the drug and its effect on DBS results </p><br>